This is a prospective, cohort, multicenter study. Cohort 1 is treatment group. All eligible subjects will receive Vebreltinib (200 mg bid po) after signing the informed consent and meeting the inclusion/exclusion criteria, until disease progression, intolerable toxicity, or death. Subjects will undergo MET abnormality testing after enrollment, including MET amplification or MET protein overexpression.
Cohort 2 is external reference group. Subjects diagnosed with CCS and met the inclusion criteria but refused to enter Cohort1 will receive the standard treatment decided by investigators. These subjects will receive follow-up. The efficacy and safety data will be collected.
Imaging evaluation will be performed using RECIST v1.1, with CT or MR plain scans every two months (±7 days) until disease recurrence or death.
During the study, subjects will receive safety follow-up, and survival follow-up will be conducted every two months after treatment, which can be done by telephone interview for approximately 3 years after treatment ends.

开始日期2025-09-30

申办/合作机构

浙江大学医学院附属第二医院（浙江省第二医院）

NCT07156604

/ Not yet recruiting临床2期IIT

Vebreltinib for Neoadjuvant Treatment in Patients With Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) Harboring METex 14 Skipping Mutant

This is a prospective, single-center phase II clinical study aimed at evaluating the efficacy and safety of Vebreltinib in neoadjuvant treatment for patients with resectable stage IIA-IIIB (N2) non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. In the study, all eligible subjects who signed the informed consent and met the inclusion and exclusion criteria were treated with Vebreltinib (200 mg bid po) for 8 weeks before surgery. The subjects were evaluated by the investigators and the surgical resection was performed within approximately 2 weeks after the neoadjuvant treatment. The study used RECIST v1.1 for imaging assessment. A CT or enhanced CT scan was conducted within 2 weeks after the end of treatment, and then every 180 days (±14) after surgery until 3 years, and then annually until disease recurrence or death, or the end of the study.

开始日期2025-09-30

申办/合作机构

复旦大学

NCT07153770

/ Not yet recruiting临床2期IIT

Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer

This study aim to evaluate the efficacy and safety of Bozitinib combined with chemotherapy as radical treatment for stage IIA-IIIC MET-altered non-small cell lung cancer

开始日期2025-09-20

申办/合作机构

上海市肺科医院

100 项与伯瑞替尼相关的临床结果

登录后查看更多信息

100 项与伯瑞替尼相关的转化医学

登录后查看更多信息

100 项与伯瑞替尼相关的专利（医药）

登录后查看更多信息

项与伯瑞替尼相关的文献（医药）

2025-11-01·Bioactive Materials

A novel organoid model retaining the glioma microenvironment for personalized drug screening and therapeutic evaluation

Article

作者: Sun, Fei ; Liu, Tong ; Wang, Jianfeng ; Yu, Shuqing ; Yang, Bao ; Zhang, Delong ; Bao, Zhaoshi ; Feng, Yutong ; Zhao, Qian ; Fu, Yiwen ; Xing, Cencan ; Jiang, Tao ; Fang, Zheng ; Zou, Donghua ; Chen, Qiaodong ; Xiao, Bo ; Ning, Shipeng ; Chen, Jiahong ; Zheng, Lemin ; Chen, Jie ; Zheng, Chengjun ; Min, Li ; Zhang, Ying ; Wang, Peng ; Yang, Yang ; Yan, Jun

Glioma is an aggressive brain tumor with a poor prognosis. Establishing an in vitro culture model that closely replicates the cellular composition and microenvironment of the original tumor has been challenging, limiting its clinical applications. Here, we present a novel approach to generate glioma organoids with a microenvironment (GlioME) from patient-derived glioma tissue. These organoids maintain the genetic and epigenetic characteristics of the primary tumor and preserve cell-to-cell interactions within the tumor microenvironment, including resident immune cells. Bulk RNA sequencing, whole exome sequencing, and DNA methylation analysis were used to confirm the molecular similarities between the organoids and primary glioma tissues. Immunofluorescence and flow cytometry were used to assess immune cell viability, comparing GlioME with floating glioma organoids. GlioME exhibited high responsiveness to chemotherapy and targeted therapy, demonstrating its potential for therapeutic screening applications. Notably, GlioME accurately predicted patient response to the recently approved MET inhibitor, vebreltinib. Thus, this organoid model provides a reliable in vitro platform for glioma microenvironment-related research and clinical drug screening.

2025-10-01·Chinese Journal of Chromatography

Determination of 13 janus kinase inhibitors in anti-alopecia cosmetics by ultra-high performance liquid chromatography-tandem triple quadrupole composite linear ion trap mass spectrometry

Article

作者: Chen, Mao-Qin ; Wang, Hai-Bo ; Fan, Lei-Lei ; Yang, Qiu-Hong

According to the Safety and Technical Specification for Cosmetics （2015）， the addition of chemical drugs to cosmetics is strictly prohibited. Anti-alopecia cosmetics are often found to contain illegal additions of prohibited drugs such as minoxidil， finasteride and other substances. Ultra-high performance liquid chromatography-tandem triple quadrupole-linear ion trap mass spectrometry （UHPLC-Q-TRAP/MS） has become a powerful technology for the simultaneous detection of illegal ingredients in cosmetics due to its advantages of rapid analysis， high sensitivity， high throughput and high selectivity. An ultra-high performance liquid chromatography-multiple reaction monitoring-information dependent acquisition-enhanced production scanning （UHPLC-MRM-IDA-EPI） method was developed to determine 13 JAK inhibitors in anti-alopecia cosmetics， including baricitinib， tofacitinib， ritlecitinib， peficitinib， abrocitinib， upadacitinib， ivarmacitinib， fedratinib， filgotinib， ruxolitinib， momelotinib， pacritinib and bozitinib. The influence of extraction solvents was investigated. Approximately 0.2 g of the sample was weighed and placed in a 50 mL graduated centrifuge tube with a cap. Then， 2 mL of 0.1% （v/v） aqueous formic acid and 10 mL of acetonitrile were added， followed by vortexing for 1 min. Subsequently， the mixture was sonicated in an ultrasonic bath for 15 min. Added 0.5 g of sodium chloride， and the mixture was centrifuged at 8 000 r/min for 8 min at 5 °C. The supernatant was transferred to another 50 mL graduated centrifuge tube with a cap. The residue was added with 10 mL of acetonitrile and the extraction procedure was repeated. After high-speed centrifugation， the supernatant was combined. The combined supernatant was added with 0.2 g of sodium chloride， and the mixture was frozen at ‒20 °C for 1 h. It was centrifuged at 8 000 r/min for 5 min at 5 °C. The acetonitrile layer was collected and filtered through a 0.22 μm organic filter membrane. The initial filtrate was discarded， and the subsequent filtrate was collected as the sample solution. A C₁₈ column was used for chromatographic separation， enabling the successful separation of the analytes within 10 min. The mobile phase consisted of 0.1% （v/v） aqueous formic acid and acetonitrile， with gradient elution applied to optimize separation efficiency. The flow rate was set at 0.3 mL/min， and the column temperature was maintained at 40 ℃ to ensure consistent performance. A fixed injection volume of 2 μL was used to guarantee reproducibility and accuracy in the analysis. This configuration enabled the rapid and reliable separation of the target compounds. For the analysis of the 13 kinds of JAK inhibitors， an ESI source operating in positive ion mode was used with MRM-IDA-EPI detection. Quantification was performed by the external standard method using matrix-matched standard solutions. Good separation of the 13 JAK inhibitors was achieved under the optimized chromatographic conditions. Calibration curves were constructed by plotting the peak area of quantitative ions against the compound mass concentration. These curves exhibited excellent linearity within the investigated concentration range， with r all exceeding 0.996. The limits of detection （LODs） and limits of quantification （LOQs） of the 13 JAK inhibitors were 1.5-1.7 ng/g and 9.2-10.9 ng/g. To validate accuracy and precision， two cosmetic matrices （water-soluble and cream） were tested at three levels： LOQ， 2×LOQ and 10×LOQ. Recoveries of the 13 JAK inhibitors ranged from 94.7% to 102.2% for the water-soluble matrix and from 92.4% to 99.2% for the cream matrix， with relative standard deviations （RSDs） ≤8.8%. This method is characterized by high efficiency， rapidity， accuracy， sensitivity and simplicity， making it a powerful tool for rapid risk screening and simultaneous quantitative analysis of JAK inhibitors in anti-alopecia cosmetics.

2025-06-01·Thoracic Cancer

Enhancing the Precision and Efficiency of Pulmonary Tumor Detection With Robotic‐Assisted ¹⁸F‐FDG PET/CT‐Guided Lung Biopsy: A Case Report

Article

作者: Liu, Jian ; Xu, Chuan ; Lu, Xia ; Li, Haiyan ; Niu, Bing ; Xu, Kai

ABSTRACT:

Sarcomatoid carcinoma, a rare and aggressive form of non‐small cell lung cancer, presents diagnostic challenges due to its heterogeneity and atypical features. This case report evaluates robotic‐assisted 18F‐FDG PET/CT‐guided percutaneous lung biopsy for improving diagnostic accuracy and efficiency in such complex lung lesions. We present the case of an 86‐year‐old male with a right upper lung lesion, chronic cough, intermittent hemoptysis, chills, and fever. Initial fiberoptic bronchoscopy and CT‐guided lung biopsy (16 min, three needle adjustments) were inconclusive. Subsequently, a robotic‐assisted PET/CT‐guided percutaneous lung biopsy was performed, targeting metabolically active regions. This procedure was completed in 6 min without any needle adjustments. This efficiency stemmed from the system's clear, precise navigation, eliminating extensive manual lesion localization and collision risk with critical structures. Unlike some navigated procedures, it avoids time‐consuming marker placement and registration. Its high accuracy guidance facilitated single needle insertion, preventing repeated adjustments, confirmatory CTs, and step‐by‐step needle advancement. Imaging confirmed a hypermetabolic lesion and mediastinal lymphadenopathy suggestive of malignancy, and histopathology revealed sarcomatoid carcinoma with pleomorphic atypical cell infiltration, high mitotic activity, and necrosis. Genetic testing identified a MET mutation, leading to targeted therapy with Bozitinib. Follow‐up imaging at 1 month showed a significant reduction in the lesion size, indicating a positive treatment response. This case underscores the potential advantages of robotic‐assisted 18F‐FDG PET/CT‐guided lung biopsy in enhancing diagnostic sensitivity and procedural efficiency by precisely targeting metabolically active areas, minimizing needle adjustments, and potentially reducing false‐negative results. Broader application in interventional radiology and oncology warrants further investigation.

252

项与伯瑞替尼相关的新闻（医药）

2025-11-18

·凯石招募

【肺癌前沿|重磅Topline】Neladalkib在多线TKI治疗后ALK阳性晚期肺癌中显示显著临床活性

临床阶段生物制药公司Nuvalent, Inc. (Nasdaq: NUVL) 于2025年11月17日宣布，其研究性ALK-选择性抑制剂neladalkib在全球ALKOVE-1 I/II期临床试验中，针对酪氨酸激酶抑制剂（TKI）预处理的晚期ALK阳性非小细胞肺癌 (NSCLC) 患者，取得了积极的顶线关键数据。此外，Nuvalent也首次公布了ALKOVE-1研究中TKI初治ALK阳性NSCLC患者探索性II期队列的初步数据。一、一文速览：Neladalkib颠覆性数据一览全球ALKOVE-1 I/II期研究结果显示：在253例经治患者中，独立盲法中心评估的客观缓解率（ORR）为31%，12个月和18个月持续缓解率（DOR）分别为64%和53%。在63例未接受过劳拉替尼治疗的患者中，ORR提升至46%，12个月和18个月 DOR分别为80%和60%。对G1202R耐药突变患者显示突出疗效，该亚组ORR达68%。颅内疗效显著，在基线伴有脑转移的患者中（n=92），颅内ORR达32%。安全性良好，因不良事件导致的停药率仅5%，剂量下调率17%。基于这些数据，公司计划与FDA召开新药申请前会议，并将在近期医学会议上公布详细结果。二、划重点| 为何我们需要“超新星” Neladalkib？ ALK阳性非小细胞肺癌约占肺癌的3-5%，虽然已有多个ALK靶向药物获批，但耐药（尤其是 G1202R、复合突变）和脑转移仍然是临床治疗的核心难题。特别是对于接受过多种ALK抑制剂治疗后进展的患者，目前尚无标准治疗方案。 Neladalkib是Nuvalent基于结构设计开发的高选择性、可脑渗透、规避TRK相关副作用的新一代ALK抑制剂，其创新设计点有： ALK选择性：专门设计避免抑制结构相关的TRK激酶，可能减少与TRK抑制相关的神经系统不良事件强效抗耐药：对G1202R等常见耐药突变保持活性，包括复合突变脑屏障穿透：专门设计用于治疗和预防脑转移三、研究设计：ALKOVE-1瞄准注册的单臂试验试验类型：全球、多中心 Phase 1/2 单臂、多队列、开放标签 RP2D（推荐II期剂量）：150 mg 每日一次。公布数据截止日期：2025.8.29。总体入组情况： 781名ALK阳性实体瘤患者接受过任意剂量neladalkib 656名ALK+ NSCLC患者接受RP2D 关键性分析人群（TKI预处理）：253名具有可测量病灶的患者（截至 2024.9.30入组且DOR随访≥6个月）四、患者画像：挑战最高难度预处理人群该研究分析人群与已上市ALK TKI的注册人群完全不同，预处理程度更重，代表了临床中的极难治群体：整体人群（n=253）：接受过中位3线治疗；78%患者接受过≥2种ALK TKI；91%为劳拉替尼经治患者；51%患者接受过化疗；40%患者基线有CNS转移；19%携带G1202R突变；17%存在复合ALK突变。未使用劳拉替尼亚组（n=63）：全部患者均为二代TKI经治；25%患者接受过化疗；35%患者基线有CNS转移；19%携带G1202R突变。五、关键疗效结果：持久缓解与高深度缓解 1. 总体TKI预处理人群 (n=253) 在253名TKI预处理的晚期ALK-阳性NSCLC患者中： ORR：31% (95%CI: 26, 37)。 DOR：估计在12个月和18个月时的DOR分别为64%和53%。 2. 劳拉替尼初治TKI预处理亚组 (n=63) 在63名劳拉替尼初治TKI预处理患者中： ORR：46% (95% CI: 33, 59)。 DOR：估计在12个月和18个月时的DOR分别为80%和60%。 3. 针对关键耐药和脑转移的疗效 ALK G1202R突变患者 (n=47)：ORR为68%，估计在12个月和18个月时的DOR分别为80%和70%。可测量CNS病灶患者 (n=92)：颅内ORR为32%，CR为13%。估计在12个月时的可达70%。 Neladalkib在ALK TKI经治患者中的疗效汇总未来展望：初治患者探索性数据令人鼓舞（n=44）初步ORR：86% DOR：范围从1.7个月到14.8个月，6和12个月的DOR为91%。 CR：9% CNS可测病灶（n=9）：ORR 78%，CR 44% 。注：基于这些积极结果，全球随机III期试验（ALKAZAR，neladalkib vs alectinib）仍在入组中。六、安全性解析：低中断率展现良好耐受性 Neladalkib展现出与其ALK-选择性、TRK-保留设计一致的良好耐受性安全性。最常见的治疗相关不良事件为转氨酶升高（ALT升高47%，AST升高44%）。其他常见事件包括便秘（28%）、味觉障碍（23%）、外周水肿（18%）。转氨酶升高多为低级别、无症状、一过性，通过剂量调整可管理。因不良事件导致的剂量下调率17%，停药率仅5%。七、公司动向：冲刺 Pre-NDA，加速注册路径 lNuvalent计划将这些关键数据提交给FDA，并安排Pre-NDA会议，以确定TKI预处理 ALK+ NSCLC患者的潜在注册路径。完整数据将在未来主要国际肿瘤大会上公布。 lNeladalkib已获得FDA授予用于经2种ALK TKI治疗的局部晚期或转移性ALK阳性NSCLC患者的突破性疗法认定和孤儿药认定。专家观点 lDana-Farber癌症研究所胸部肿瘤专家、ALKOVE-1研究研究者Alice T. Shaw博士表示：“在治疗ALK阳性肺癌时，我们的目标不仅是让患者活得更久，还要让他们活得更好。这些令人鼓舞的数据表明，neladalkib可能代表ALK阳性肺癌的一种新的差异化治疗选择，在提供持久临床获益的同时，可能减少影响生活质量的副作用风险。” lALK Positive Inc董事会主席Kirk Smith认为：“这一宣布为ALK阳性肺癌的潜在预后转变增添了新的证据，给患者带来了新的希望。我们鼓励继续创新和开发新的治疗选择，希望有一天，晚期ALK阳性NSCLC能够更多地作为一种慢性病而非危及生命的疾病来管理。” Neladalkib在ALKOVE-1研究中的成功，标志着ALK阳性肺癌治疗向“精准再精准”迈出了关键一步。其针对最难治人群展现出的持久疗效、卓越的颅内活性以及因其高选择性而带来的良好耐受性，共同构成了其成为“同类最优”疗法的潜力。随着与FDA的pre-NDA会议提上日程，我们期待这款新一代ALK抑制剂能加速其临床应用的步伐，为历经多线治疗、陷入困境的患者带来新的生命曙光，并将晚期ALK阳性肺癌真正转变为一种可长期管理的慢性疾病。现有多项肺癌临床试验正在各大医院招募肿瘤患者，欢迎咨询！项目靶点适应症要求 ASN-3186 SMARCA4 非小细胞肺癌 ≥18岁，至少一线治疗失败 NW-101 TCR-T疗法肺鳞癌 18~70岁，标准治疗失败 ANS014004 MET 肺癌 ≥18 岁，标准治疗失败 GC101 TIL疗法肺癌 18~75岁，含铂标准治疗失败马来酸奈拉替尼片 EGFR 肺腺癌 ≥18 岁，EGFR罕见突变，包括 18 外显子 G719X、E709X 等 TL139 ALK 肺癌 ≥18岁，经ALK二代TKI治疗进展 AST2303片 EGFR C797S 肺癌 ≥18岁，未接受过靶向C797S突变的抗肿瘤治疗 SY-5933片联合CT-707片 KRAS G12C 肺癌 ≥18岁，标准治疗失败 AMX3009 EGFR 肺癌 ≥18岁，罕见 EGFR 突变（L861Q、G719X、S768I 和E709X） WSD0922-FU EGFR 肺癌伴脑膜转移 ≥18岁，既往接受第三代EGFR-TKI治疗后疾病进展 GT201 TIL疗法肺癌 18~60岁，至少接受过一线系统化治疗 TR128 RAF/RAS 肺癌 ≥18岁，至少一线治疗失败伯瑞替尼联合含铂双药化疗 MET 肺癌 ≥18岁，经EGFR-TKI治疗失败马来酸苏特替尼 EGFR 肺癌 ≥18岁，EGFR罕见突变伯瑞替尼 MET MET 14肺癌 ≥18岁，初治或经治 QLC1101联合用药 KRAS G12D 肺癌 ≥18岁，标准治疗失败 HLX43 ADC药物肺癌 ≥18岁，标准治疗失败 KY0118 PD1/IL2融合蛋白非小细胞肺癌、胰腺癌、肠癌、黑色素瘤 18<75岁，经局部治疗或局部治疗后进展均可 NW-301 TCR-T疗法肺鳞癌，胰腺癌，结肠癌 18 岁至 70 岁，两线化疗以后即可入组 YSCH-01 瘤内给药非小细胞肺癌、三阴乳腺癌、脂肪肉瘤 ≥18 岁，标准治疗失败 NEUK200-13 CAR-NK细胞疗法小细胞肺癌 18<75岁，标准治疗失败 TR64 双靶点抑制剂小细胞肺癌伴脑转 18≤75 岁，标准治疗失败凯石招募——临床试验招募平台肿瘤患者申请参加临床试验须知：参与临床试验的患者，可以免费用试验新药，与试验相关的检查也是免费的。目前有CAR-T、TIL等细胞疗法，PD-1/PD-L1等免疫治疗药物，小分子抑制剂、双抗、单抗、ADC等靶向药物的临床试验正在进行中。正在招募肺癌、食管癌、肝癌、胃癌、结直肠癌、宫颈癌、卵巢癌、乳腺癌、胆管癌、子宫内膜癌、黑色素瘤、肉瘤、恶性血液疾病、淋巴瘤等各种恶性肿瘤，想要了解或者参加临床试验项目，可以咨询我们医学部的老师。企业商务合作请联系：18516873961 👉点击上面公众号名片关注我们👈

2025-11-18

·GlobeNewswire-Health Care

Apollomics Announces Changes to its Board of Directors and Composition of Committees

FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company’s board of directors (“Board”) and composition of committees. On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board. Mr. Hsueh’s resignation was not related to any disagreement with the Company. Pursuant to a meeting of the Board on November 16, 2025, Dr. Ya-Chi (Claudia) Huang was appointed to the Board to fill the vacancy resulting from Mr. Hsueh’s resignation. Dr. Ya-Chi (Claudia) Huang will also replace Mr. Po-Jen Hsueh as a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee. Following these changes and the previously announced appointments of directors, the Company’s Board is comprised of the following seven members: Hung-Wen (Howard) Chen (Chairman), Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang. Moses Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang are independent directors. Biographical Information of the New Director Dr. Ya-Chi (Claudia) Huang brings to the Board extensive experience in biotechnology investment, corporate governance, and research and development across Taiwan's biopharmaceutical industry. Dr. Huang currently serves as Assistant Vice President at Maxpro Ventures, where she leads domestic and international investment activities. Since joining in 2024, she has successfully completed investments in multiple companies and manages their post-investment operations. She also serves as a director of AngenMed Therapeutics. Previously, Dr. Huang served as Investment Manager at Diamond Biofund (6901.TW), where she independently completed multiple investments and oversaw post-investment management for all of Diamond's portfolio companies. She participated in Diamond Biofund's IPO on the Taiwan Stock Exchange in 2023. Earlier in her career, she was Deputy Manager in the Research Department at Fubon Securities Investment Services, where she evaluated over 150 unlisted biotech companies in Taiwan, China, and Hong Kong, and contributed to a significant increase in Fubon Securities' investment banking profits. Dr. Huang's scientific background includes research positions at the National Health Research Institutes, Development Center for Biotechnology, and Academia Sinica. Her doctoral research on Epstein-Barr virus was published in Blood and received the Distinguished Thesis Prize in the 12th TienTe Lee Biomedical Award. Dr. Huang holds a Ph.D. in Microbiology from National Taiwan University College of Medicine and an M.S. in Biological Sciences from National Sun Yat-sen University. About Apollomics Inc.Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries. For more information, please visit www.apollomicsinc.com. Cautionary Statement Regarding Forward-Looking StatementsThis press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2024, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. Investor Contacts: Apollomics: Peter Lin, Chief Financial Officer Apollomics, Inc. Phone: 1-650-209-4055 Email: peter.lin@apollomicsinc.com

临床2期高管变更IPO

2025-11-17

·腾讯网

80 岁肺癌，TKI 能常规使用吗？一文解答老年肺癌诊疗要点

肺癌是我国癌症发病率与死亡率均居首位的恶性肿瘤，且在 65 岁以上人群中发病率显著上升[1-2]。随着人口老龄化进程加剧，老年肺癌患者数量及其在肺癌人群中的占比持续攀升，因此，规范化老年肺癌诊疗显得尤为重要。近期，中国临床肿瘤学会老年肿瘤防治专家委员会重磅发布《老年晚期肺癌治疗专家共识（2025 版）》（以下简称《共识》）[2]，在既往 2022 版《共识》[3]的基础上，进一步就老年人群分层定义及特点、老年晚期肺癌患者综合评估、老年晚期非小细胞肺癌（NSCLC）及广泛期小细胞肺癌（ES-SCLC）患者精准治疗、老年肺癌治疗不良反应管理五大方面进行了全面修订和更新。本文结合该专家共识及相关文献，总结了当前老年肺癌诊疗现状及未来发展趋势，以期为老年肺癌临床诊疗提供参考。一、老年人群定义、全球老龄化危机及老年肺癌流行病学目前世界卫生组织（WHO）将 65 岁定义为多数国家统计老龄化的基准年龄；在低收入国家和地区建议将这一基准年龄降至 60 岁。而 2025 版《共识》指出，在肿瘤领域，国际权威机构对老年肿瘤患者的定义尚无统一标准：美国国立综合癌症网络（NCCN）将 65 岁及以上的恶性肿瘤患者定义为老年恶性肿瘤人群（2006 年至 2025 年 3 月）[4]；国际老年肿瘤学会（SIOG）与欧洲肿瘤内科学会（ESMO）则推荐采用 70 岁作为老年肿瘤患者的基准年龄分界。美国国立癌症研究所（NCI）建立的监测、流行病学和最终结果（SEER）数据库数据显示，65 岁是恶性肿瘤发病率和死亡率的显著拐点，该年龄以上人群恶性肿瘤发病率为 1.96%，死亡率为 0.93%，较 65 岁以下人群分别升高 8.9 倍和 17.9 倍。基于此，共识意见 1 指出：65 岁以上老年晚期肺癌患者在临床诊疗中根据年龄分层进一步分为低龄老年人（65～74 岁）、中龄老年人（75~84 岁）和高龄老年人（85 岁及以上），在诊疗时需给予特别关注（证据级别：中，推荐等级：高）。二、老年肿瘤患者两大临床挑战共识指出老年肿瘤患者临床诊疗往往面临机体功能及合并基础疾病两大挑战：一方面随着年龄增长，老年患者机体多系统功能加速衰退，药物耐受性降低。多器官储备功能下降严重影响其对抗肿瘤药物的吸收、分布、代谢和排泄，增加了临床治疗方案选择和剂量优化难度。此外，老年患者基础疾病增多，合并用药比例随之升高：中国国家卫健委数据显示，中国 65 岁以上人群慢性病共患率较 55～64 岁人群提高 29%。老年肺癌患者同时罹患 2 种及以上慢性疾病（以下称为共病）尤为普遍，因此导致的多重用药在老年肿瘤患者中极为常见，不仅加重肝肾负担，在抗肿瘤治疗期间更可能增加药物蓄积风险。上述因素（器官功能衰退、共病及多重用药）共同导致老年肺癌患者在治疗策略选择上无法与低龄患者一致，这种局限性是影响其预后的重要因素。三、老年肺癌诊断、治疗特点共识意见 2 指出：老年晚期肺癌患者临床实践须重视老年综合评估（CGA），结合量表及患者个体差异，通过多学科协作优化治疗决策，最终实现生活质量的提高和生存期的延长（证据级别：中，推荐等级：高）。CGA 可全面评估老年患者的躯体功能状态、治疗风险、营养状况、合并症及合并用药、认知及心理状态等综合指标，评估常规肿瘤治疗中易疏漏的老年问题，并预测治疗相关毒性及不良反应风险。此外，通过选择合适的量表工具，结合肿瘤生物学行为、患者体能状态及合并症，还可以进一步预测生存期与预后。在治疗期间可通过针对性识别和管理疼痛、呼吸困难、疲乏等症状，关注患者的心理社会需求，从而确保患者在生存期内获得最佳生活质量，实现更好的治疗获益。表 1：老年肺癌患者评估常用量表工具在老年肺癌患者临床治疗方面，老年晚期 NSCLC 患者的治疗原则总体与非老年患者一致，但在具体治疗决策过程中需结合老年综合评估、年龄分层及体力状态等因素，具体流程如下图：图 1：老年晚期肺癌患者进行老年评估的流程图1驱动基因阳性老年晚期 NSCLC靶向治疗共识意见 3：驱动基因阳性老年晚期 NSCLC 患者均推荐优选靶向治疗，可结合突变类型、年龄分层及老年综合评估选择合适的联合治疗方案（证据级别：高，推荐等级：强）。不同靶向相关代表药物：EGFR 突变：第三代靶向表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）：奥希替尼、阿美替尼、伏美替尼等；ALK 重排或融合：阿来替尼、布格替尼、洛拉替尼等；MET 外显子 14 跳跃突变：卡马替尼、赛沃替尼、伯瑞替尼等；ROS1 融合基因阳性：克唑替尼、恩曲替尼；RET 融合：普拉替尼、塞普替尼；NTRK 融合基因阳性：恩曲替尼、拉罗替尼；大多数靶向药物的 III 期临床研究均对年龄进行了分层分析，结果显示，老年与非老年患者获益一致，故国内外指南中靶向治疗药物推荐未对年龄有限制。化学治疗共识意见 4：拟行化疗的老年晚期 NSCLC 患者应结合年龄分层、老年综合评估选择合适的化疗方案，以减少不良反应，提高疗效（证据级别：中，推荐等级：强）。ADC 药物共识意见 5：抗体偶联药物（ADC）目前可推荐在低龄老年晚期 NSCLC 患者后线治疗中使用（证据级别：弱，推荐等级：强）。目前尚无证据支持高龄老年肺癌患者接受化疗治疗，但既往研究数据显示化疗及 ADC 药物治疗老年患者整体安全性可控，耐受性良好。然而，鉴于老年患者通常合并较多基础疾病和伴有生理功能减退等因素，因此在治疗过程中，除需严格评估患者骨髓抑制、心脏毒性及神经不良反应风险，同时应关注衰弱状态及合并症对患者预后的影响。免疫治疗共识意见 6：对于不耐受化疗的驱动基因阴性老年晚期 NSCLC 患者，推荐阿替利珠单抗单药治疗；对于程序性死亡受体配体 1（PD-L1）表达阳性的驱动基因阴性老年晚期 NSCLC 患者，也可选择帕博利珠单抗单药治疗（证据级别：高，推荐等级：强）。共识意见 7：对于可耐受化疗的驱动基因阴性老年晚期 NSCLC 患者（低龄、中龄）推荐免疫联合化疗，但需结合老年综合评估选择合适的化疗方案（证据级别：高，推荐等级：强）。免疫治疗已成为驱动基因阴性晚期 NSCLC 患者的标准治疗，老年患者接受免疫治疗同样有获益趋势，但仍需综合考虑老年综合评估、PD-L1 表达状态、年龄等因素，选择最佳治疗方案。在驱动基因阴性的老年晚期 NSCLC 患者治疗中，单药免疫可适用于不耐受含铂化疗和 PD-L1 表达阳性的的老年人群，但老年患者是否选择免疫联合方案应根据老年综合评估结果及年龄分层进行考量。由于目前针对高龄老年患者的研究有限，未来应积极开展更多临床研究，以期为老年患者带来更多获益。2老年 ES-SCLC 治疗共识意见 8：对于老年 ES-SCLC 人群，需结合年龄分层及老年综合评估，优选免疫联合化疗 + 抗血管一线治疗（证据级别：高，推荐等级：强）。免疫治疗联合化疗化疗药物选择通常推荐含铂双药联合方案，如依托泊苷联合卡铂或顺铂。对于 PS 评分较好且基础状态良好的老年患者，可考虑标准剂量；基础状态差或有危险因素的患者则建议采用低剂量含铂方案（卡铂与顺铂疗效相当，但卡铂较顺铂的耐受性更佳）；对于 PS 评分高且基础状态较差的老年患者，口服单药依托泊苷也是一种选择，但需密切监测其骨髓抑制等不良反应。免疫治疗联合抗血管药物III 期 ETER701 显示贝莫苏拜单抗联合化疗 + 安罗替尼治疗 ≥ 65 岁患者可带来一定的 OS 获益趋势（HR=0.54，95%CI：0.35～0.81），提示免疫联合化疗 + 抗血管药物方案也是老年 ES-SCLC 患者的一线可选方案。3治疗不良反应管理共识意见 9：针对老年患者的特点，应选择疗效确切且安全性相对更好的药物。治疗过程中需更加注意药物之间的相互作用，加强监测，及时识别和处理不良反应（证据级别：中，推荐等级：强）。结合老年晚期肺癌患者的个体差异，建议选择疗效确切且安全性相对更好的药物。同时在治疗过程中，还需注意药物之间的相互作用，加强监测，及时识别和处理不良反应，具体如下：表 2. 老年晚期肺癌常用抗肿瘤药物与其他合并药物的相互作用另外，多学科管理在老年不良反应管理也发挥着较大价值。表 3. 老年晚期肺癌多学科指导下的药物常见不良反应处理原则四、老年肺癌临床研究1、靶向治疗EGFR-TKI：大多数靶向药物的 III 期临床研究年龄分层分析结果显示，老年与非老年患者获益一致，故国内外指南中此类药物推荐未对年龄有限制。ALK-TKI：在低、中龄老年 ALK 阳性 NSCLC 患者中获益与总体人群相似。以阿来替尼为代表的 ALK-TKI 在不同年龄段的患者均有获益趋势，但是目前针对老年患者的现有证据有限，仍需进一步证实。MET ex14 跳跃突变：特泊替尼、赛沃替尼、伯瑞替尼、卡马替尼、谷美替尼等可用于治疗老年 MET ex14 的 NSCLC 患者；但目前研究有限，仍需更多探索。2、化疗[2,5]单药化疗：低-中龄老年人群可耐受单药化疗并获益；高龄老年人群，目前尚无支持单药化疗的证据。双药化疗：低、中龄老年人群双药化疗较单药化疗获益更大；对于高龄老年人群，目前尚无支持单药化疗的证据。节拍/减剂量化疗：对于单药化疗不耐受人群，节拍/减剂量治疗可降低化疗剂量并增加给药频率，通过长时间不间断给药以达到延长血浆活性药物稳态浓度的目的。研究显示低龄老年人群能够从中获益；对于中、高龄老年人群，目前尚无支持节拍化疗的证据。3、ADC 治疗Dato-DXd（中国国家药品监督管理局 [NMPA] 正在受理上市申请）：65～75 岁患者给药时无需调整剂量，但目前尚无更细的老年分层证据。治疗总体安全性可控，需重点监测骨髓抑制、心脏毒性、神经毒性及衰弱/合并症影响。4、免疫治疗[2,6-7]以免疫为基础的治疗方案已成为驱动基因阴性晚期 NSCLC 患者的标准治疗，其治疗模式包括免疫单药、化免联合、免疫联合抗血管及双免联合。单免治疗：IMpower110 研究、KEYNOTE-024 研究、KEYNOTE-042 研究、EMPOWER-Lung1 等研究的亚组数据显示，免疫单药方案能够改善 ≥ 65 岁 PD-L1 高表达 NSCLC 患者的生存时间。意大利胸部肿瘤学会国际专家小组会议也提出免疫单药适用于 PD-L1 高表达的老年晚期 NSCLC 患者。针对中龄老年人群，KEYNOTE-024、KEYNOTE-042 研究的荟萃分析显示，相较于化疗，帕博利珠单抗单药治疗在 ≥ 75 岁且 PD-L1 高表达的晚期 NSCLC 患者 OS 获益更优。而对于 ≥ 85 岁的高龄老年人群，目前研究数据有限。免疫 + 抗血管治疗：在免疫联合抗血管药物治疗方面，低龄老年人群有获益；对于中、高龄老年人群，暂无证据。因此，对于可耐受化疗的驱动基因阴性老年晚期 NSCLC 患者（低龄、中龄）推荐化免联合疗法，但需结合老年综合评估选择合适的化疗方案。而因纳入老年患者的免疫联合抗血管药物研究有限，未来仍需开展更多研究进行探索。双免 + 化疗：低龄老年人群有获益；对于中、高龄老年人群，暂无证据。在双免治疗方面，低龄老年人群有获益，对于中龄老年人群，CheckMate-227 研究亚组分析提示，在 ≥ 75 岁晚期 NSCLC 患者中，纳武利尤单抗联合伊匹木单抗组相较于化疗组 OS 获益趋势并不明显（13.5 vs.11.4 个月，HR=0.92，95% CI：0.57～1.48）。对于高龄老年人群，目前暂无证据。由于双免 ± 化疗治疗在老年患者中获益趋势并不一致，所以未来仍需开展更多的临床研究进一步探索与验证。此外，对于免疫治疗在老年患者中的安全性问题，各免疫药物说明书显示，免疫治疗在老年患者与非老年患者中安全性总体相似，且总体可控。但需要关注随着年龄增长，不良事件风险相对提高以及治疗中断率相应增加的问题。5、小细胞肺癌免疫治疗[2,7]化免联合：在免疫联合化疗方面，相关研究显示，在 ≥ 65 岁、ECOG PS=0-1 分的老年患者中，化免联合方案对 ES-SCLC 患者均有生存获益趋势。但对于中、高龄老年人群，目前暂无证据。化免联合 + 抗血管药物：对于低龄、中龄老年人群，III 期 ETER701 研究亚组分析结果显示，相较于安慰剂组，贝莫苏拜单抗联合化疗 + 安罗替尼一线治疗 ≥ 65 岁 ES-SCLC 患者，OS 有获益趋势（HR=0.54，95% CI：0.35～0.81）。这些结果提示免疫联合化疗 + 抗血管药物方案也是老年 ES-SCLC 患者的一线可选方案，整体安全性可控，但特别需要关注患者的基础状态以及在治疗过程中的相关不良事件。对于高龄老年人群，目前暂无证据，未来仍需更多临床研究的探索。总结与展望2025 版《共识》的发布为我国老年晚期肺癌的临床工作提供了重要的临床参考和指导，进一步推动了老年晚期肺癌诊疗的合理化和规范化，但未来老年肿瘤患者治疗，仍有许多工作亟待推进。当前老年晚期肺癌的精准评估虽为风险预测提供依据，但缺乏大规模前瞻性研究数据，限制了其在临床决策中的充分应用，因此临床亟需普及老年综合评估工具以优化治疗方案选择。同时，临床试验中老年（尤其高龄）患者入组比例不足，导致现有数据指导价值有限，未来新药研发需强化针对老年群体的疗效与安全性评估，并积极探索新型疗法。不良反应管理应构建「预测-干预」闭环体系实现主动防控。展望未来，多模态组学突破与人工智能（AI）技术有望革新诊疗模式，亟需加速相关研究与新技术的临床转化，以切实改善老年患者的预后与生活质量。未来需通过更多的临床研究，进一步规范老年患者机体机能的全面评估、不良反应的管理及治疗方案的优化，实现老年肺癌患者获益最大化。参考文献[1] Wu Y, He S, Cao M, et al. Comparative analysis of cancer statistics in China and the United States in 2024. Chin Med J (Engl). 2024, 20, 137(24): 3093-3100. [2] 中国临床肿瘤学会老年肿瘤防治专家委员会. 老年晚期肺癌治疗专家共识（2025版）[J]. 中华肿瘤杂志, 2025, 网络预发表.[3] 中国老年保健协会肺癌专业委员会, 北京肿瘤学会肺癌专业委员会. 老年晚期肺癌内科治疗中国专家共识(2022版)[J]. 中国肺癌杂志, 2022, 25(6): 363-384. [4] National ComprehensiveCancer Network. NCCN guidelines: older adult oncology, 2version. 2025[EB/OL]. [2025-05-22].[5] 王秋明, 林英城, 林雯, 等. 老年人晚期非小细胞肺癌化疗疗效及预后分析[J]. 肿瘤研究与临床, 2011, 23(8): 522-525. [6] Tsukita Y, Tozuka T, Kushiro K, et al. Immunotherapy or chemoimmunotherapy in older adults with advanced non-small cell lung cancer[J]. JAMA Oncol, 2024, 10(4): 439-447.[7] 中国临床肿瘤学会小细胞肺癌专家委员会, 中国医师协会肿瘤多学科诊疗专业委员会. 小细胞肺癌免疫治疗专家共识(2025版)[J]. 中华肿瘤杂志, 2025, 47(1): 65-75.整理：王福栋；编辑：Bree题图：图虫创意

临床研究临床结果

100 项与伯瑞替尼相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
MET基因扩增非小细胞肺癌	中国	北京浦润奥生物科技有限责任公司	2025-06-24
IDH突变星形细胞瘤	中国	北京浦润奥生物科技有限责任公司	2024-04-17
胶质母细胞瘤	中国	北京浦润奥生物科技有限责任公司	2024-04-17
MET外显子14跳变的非小细胞肺癌	中国	北京浦润奥生物科技有限责任公司	2023-11-14

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性非鳞状非小细胞肺癌	临床3期	中国	北京浦润奥生物科技有限责任公司	2025-07-07
非小细胞肺癌	临床3期	-	北京鞍石生物科技股份有限公司	2025-05-15
前列腺癌	临床3期	-	北京鞍石生物科技股份有限公司	2025-05-15
局部晚期非小细胞肺癌	临床2期	中国	北京鞍石生物科技股份有限公司	2024-08-07
EGFR突变的非小细胞肺癌	临床2期	美国	Apollomics, Inc. (United States)	2022-01-18
转移性非小细胞肺癌	临床2期	美国	Apollomics, Inc. (United States)	2022-01-18
晚期非小细胞肺癌	临床2期	中国	北京浦润奥生物科技有限责任公司	2020-01-17
c-Met阳性非小细胞肺癌	临床2期	中国	北京浦润奥生物科技有限责任公司	2020-01-06
转移性透明细胞性肾细胞癌	临床2期	澳大利亚	Apollomics (Australia) Pty Ltd.	2018-09-05
转移性透明细胞性肾细胞癌	临床2期	新西兰	Apollomics (Australia) Pty Ltd.	2018-09-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04258033 (KUNPENG, Company_Website) 人工标引	临床2期	非小细胞肺癌 MET Amplification	86	伯瑞替尼	鑰範艱簾範選鬱鹽築壓(製願顧廠衊積衊蓋構糧) = 醖襯構積顧願醖遞選襯衊構願壓鹹積衊餘衊網 (糧壓壓觸醖積夢襯艱範 ) 更多	积极	2025-06-30
				伯瑞替尼 (队列2：标准治疗（含铂化疗方案）失败的MET扩增经治患者)	鑰範艱簾範選鬱鹽築壓(製願顧廠衊積衊蓋構糧) = 夢範築積衊網餘願窪獵衊構願壓鹹積衊餘衊網 (糧壓壓觸醖積夢襯艱範 ) 更多
NCT06343064 (phase Ib/II study, ASCO2025)	临床1/2期	EGFR突变的非小细胞肺癌 METamp positive \| METov	56	Vebreltinib 150 mg BID + PLB1004 80 mg QD	襯膚鹹鑰選積鹹襯顧窪(鹹簾夢鏇繭廠繭獵構構) = 60.7% 餘醖糧憲繭築衊衊鬱鹹 (願壓膚襯壓獵鏇鏇壓遞 ) 更多	积极	2025-05-30
NCT04258033 \| NCT03175224 (SPARTA-II, ESMO2024) 人工标引	临床2期	MET外显子14跳变的非小细胞肺癌 MET Exon 14 Skipping	107	Vebreltinib 200 mg BID	膚糧築觸積鹹艱鹹網糧(齋積範壓築壓膚膚鬱憲) = 築夢範糧願鬱簾蓋築簾鏇蓋膚鑰網夢蓋艱鏇築 (願憲網製積選繭齋鬱膚 ) 更多	积极	2024-09-14
				Vebreltinib Vebreltinib 200 mg BID (previously treated)	遞願鬱觸壓構積繭鹹蓋(顧遞窪獵餘積選繭艱廠) = 繭積窪蓋廠構醖襯衊築鹹鏇遞鹽窪壓築糧窪廠 (鑰齋鹽鑰鏇衊膚範襯選, 43.5 ~ 76.9) 更多
NCT06343064 (WCLC2024) 人工标引	临床1/2期	EGFR突变MET阳性非小细胞肺癌 MET Overexpression \| MET Amplification \| EGFR Mutation	44	Vebreltinib 100mg plus PLB1004 160mg	範鏇顧獵壓築夢齋廠餘(襯繭膚鑰觸繭衊築鹽膚) = 顧艱鏇蓋遞餘構構糧膚廠鹽鬱鏇積繭憲艱顧鏇 (蓋鹹鏇製積壓顧壓築夢 )	积极	2024-09-10
				Vebreltinib 150mg plus PLB1004 160mg	範鏇顧獵壓築夢齋廠餘(襯繭膚鑰觸繭衊築鹽膚) = 繭壓窪鹽觸製繭夢艱衊廠鹽鬱鏇積繭憲艱顧鏇 (蓋鹹鏇製積壓顧壓築夢 )
NCT03175224 (SPARTA, GlobeNewswire) 人工标引	临床2期	实体瘤 MET Fusion	14	Vebreltinib	願餘製網鑰蓋鏇繭遞齋(膚觸築艱願鏇鑰築網製) = 獵築艱網膚壓願選淵願膚範願窪獵鹹憲網繭遞 (廠壓願壓顧餘餘範鑰艱 ) 更多	积极	2024-08-13
NCT04258033 (KUNPENG, Literature \| Pubmed \| J Clin Oncol) 人工标引	临床2期	MET外显子14跳变的非小细胞肺癌 MET Exon 14 Skipping (Activating)	52	Vebreltinib 200 mg	廠網齋製鏇窪餘鏇膚範(廠願蓋鑰獵顧廠簾夢窪) = 憲壓鑰選選餘獵鹽壓鑰蓋窪膚選選鹹艱衊簾餘 (餘構築醖襯選糧夢鑰窪, 61.1 ~ 86) 更多	积极	2024-07-26
				Vebreltinib 200 mg (treatment-naïve)	廠網齋製鏇窪餘鏇膚範(廠願蓋鑰獵顧廠簾夢窪) = 遞獵餘範鬱淵網壓鬱鏇蓋窪膚選選鹹艱衊簾餘 (餘構築醖襯選糧夢鑰窪, 59.9 ~ 89.6)
NCT04258033 (KUNPENG, ASCO2024) 人工标引	临床2期	MET外显子14跳变的非小细胞肺癌 MET Exon 14 Skipping	135	Vebreltinib 200 mg	鹽鹹膚鑰鏇襯淵鹹獵衊(獵鏇襯鬱鑰膚網窪構鏇) = 觸餘鬱齋鹽醖繭醖窪鑰網衊醖鬱夢獵窪蓋願繭 (憲蓋壓繭繭膚遞蓋壓衊, 61.1 ~ 86.0) 更多	积极	2024-05-24
				Vebreltinib 200 mg (pts with any baseline brain metastases)	鹽鹹膚鑰鏇襯淵鹹獵衊(獵鏇襯鬱鑰膚網窪構鏇) = 遞觸鏇艱網製壓糧築鹹網衊醖鬱夢獵窪蓋願繭 (憲蓋壓繭繭膚遞蓋壓衊 )
NCT06105619 (FUGEN, ASCO2024)	临床2/3期	胶质母细胞瘤 PTPRZ1-MET Fusion gene positive	84	Vebreltinib 300 mg	製鹽遞壓壓鹽憲壓醖獵(選艱壓淵淵餘築簾網蓋) = 顧膚鹹觸鏇齋蓋構膚築艱構鹹遞衊遞糧網廠膚 (蓋壓憲廠鑰遞衊鹹構憲, 4.44 ~ 8.77) 更多	积极	2024-05-24
				Chemotherapy (temozolomide or cis-platinum combined with etoposide)	製鹽遞壓壓鹽憲壓醖獵(選艱壓淵淵餘築簾網蓋) = 餘窪顧簾壓鏇製艱製選艱構鹹遞衊遞糧網廠膚 (蓋壓憲廠鑰遞衊鹹構憲, 2.37 ~ 4.27) 更多
NCT04258033 (Pubmed)	临床2期	MET外显子14跳变的非小细胞肺癌二线 MET exon 14 skipping mutation	1	Tepotinib	餘遞鹽觸願範壓鏇襯膚(艱鹹齋構襯願夢網範繭) = 構夢遞願衊積繭範觸繭壓構構衊範製製艱憲憲 (齋範觸餘鬱選壓願衊遞 )	积极	2024-01-01
				Vebreltinib	餘遞鹽觸願範壓鏇襯膚(艱鹹齋構襯願夢網範繭) = 願鏇壓齋醖艱醖顧構願壓構構衊範製製艱憲憲 (齋範觸餘鬱選壓願衊遞 ) 更多
NCT04258033 \| NCT03175224 (SPARTA, Biospace) 人工标引	临床2期	MET外显子14跳变的非小细胞肺癌 MET Exon 14 Skipping	500	Vebreltinib (gene copy number<4)	繭膚廠範鬱網艱繭衊繭(醖顧膚構艱願艱醖憲遞) = 構範簾壓憲築築艱衊艱憲窪衊淵齋廠淵糧繭艱 (獵鬱淵獵鹽餘膚鹽衊憲 ) 更多	积极	2023-12-04
				Vebreltinib (GCN≥4)	繭膚廠範鬱網艱繭衊繭(醖顧膚構艱願艱醖憲遞) = 膚鏇蓋憲廠獵鏇鹹憲製憲窪衊淵齋廠淵糧繭艱 (獵鬱淵獵鹽餘膚鹽衊憲 ) 更多